TDAC
Translational Development Acquisition Corp.
Key Financials
Total Assets
$181.7M
↑ 3.8%
Net Income
$6.4M
↑ 9059.7%
Operating Income
$-944538
↓ 381.0%
Cash & Equivalents
$29787.00
↓ 93.2%
Total Liabilities
$6.6M
↑ 5.3%
Shareholders' Equity
$-6542108.00
↓ 16.9%
Operating Cash Flow
$-608387.00
↑ 28.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 425 | 6/15/2026 | View on SEC |
| 8-K | 6/12/2026 | View on SEC |
| 425 | 6/10/2026 | View on SEC |
| 425 | 6/2/2026 | View on SEC |
| SCHEDULE 13G | 6/2/2026 | View on SEC |
| 4 | 5/29/2026 | View on SEC |
| DEFA14A | 5/28/2026 | View on SEC |
| DEF 14A | 5/27/2026 | View on SEC |
| 425 | 5/27/2026 | View on SEC |
| 8-K | 5/27/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | TDAC |
| Company Name | Translational Development Acquisition Corp. |
| CIK | 1926599 |
| Sector | Blank Checks |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 6770 |
| SIC Description | Blank Checks |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | (413) 204-2769 |